Abstract
The article discusses the development of cancer therapies which would use the immune system, especially CD8+ and CD4+ T cells, to attack malignant cells and destroy tumors. The author discusses the elements of making a cancer vaccine, looking at the identification of antigens, the method of delivery, and at what stage the treatment should be administered. Provenge, a vaccine developed by the pharmaceutical company Dendreon to treat advanced prostate cancer, is examined. Coley's toxin, a bacterial vaccination against cancer developed by the doctor William B. Coley, the immune surveillance theory, suggested by the scientist Paul Ehrlich, and immunotherapy treatments created by Steven Rosenberg at the U.S. National Cancer Institute (NCI) are discussed.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
